Based on the results of DESTINY-Breast04, the benefit from T-DXd administration has been extended to patients with HER2-low breast cancer, defined as IHC 2+ with negative results on in situ hybridization (ISH) or IHC 1+ [24]. Here, ERBB2 is linked to breast cancer.